Delayed B cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive natural killer cells.
Antía MoreiraElvira MunteisAndrea VeraAdrián Macías GómezBernat Bertrán RecasensMiguel Ángel Rubio PérezMireia LlopJose E Martínez-RodríguezPublished in: European journal of neurology (2022)
Adaptive NKG2C+ NK cells in RRMS may be associated with delayed B cell repopulation after rituximab, a finding probably related to enhanced depletion of B cells exerted by NK-cell-mediated ADCC, pointing to the use of personalized regimens with anti-CD20 monoclonal antibody therapy in some patients.
Keyphrases
- nk cells
- monoclonal antibody
- multiple sclerosis
- natural killer cells
- end stage renal disease
- diffuse large b cell lymphoma
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- stem cells
- chronic lymphocytic leukemia
- patient reported outcomes
- replacement therapy
- smoking cessation
- combination therapy
- drug induced